VeriMomoligopeptide-126 sh-oligopeptide-1 est-il sûr pendant la grossesse ?
No harmonised CLP reproductive classifications (ECHA Annex VI) or CIR/SCCS safety opinions identify reproductive or developmental hazard for cosmetic use of EGF/oligopeptide ingredients. Peer‑reviewed literature documents biological activity of EGF in tissues but does not provide evidence of maternal reproductive toxicity following topical cosmetic use; dermal bioavailability of large peptides is expected to be negligible (sources: ECHA Annex VI (no harmonised H360/H361), CIR/SCCS absence of adverse findings in cosmetic peptide assessments, PubMed literature on EGF topical use).
Related ingredients
Frequently asked questions
- oligopeptide-126 sh-oligopeptide-1 est-il sûr pendant la grossesse ?
- No harmonised CLP reproductive classifications (ECHA Annex VI) or CIR/SCCS safety opinions identify reproductive or developmental hazard for cosmetic use of EGF/oligopeptide ingredients. Peer‑reviewed literature documents biological activity of EGF in tissues but does not provide evidence of maternal reproductive toxicity following topical cosmetic use; dermal bioavailability of large peptides is expected to be negligible (sources: ECHA Annex VI (no harmonised H360/H361), CIR/SCCS absence of adverse findings in cosmetic peptide assessments, PubMed literature on EGF topical use).
- oligopeptide-126 sh-oligopeptide-1 est-il sûr pendant l'allaitement ?
- No evidence from regulatory sources or peer‑reviewed studies that topical oligopeptide‑1 causes reproductive or lactation toxicity or transfers into breastmilk after cosmetic topical use; expected negligible systemic absorption of large peptides reduces lactational exposure (sources: PubMed, CosIng, PubChem entries for peptide cosmetic ingredients; no harmonised CLP classifications).
- oligopeptide-126 sh-oligopeptide-1 est-il sûr pour la peau de bébé ?
- Hazard and mechanism: no specific developmental or reproductive hazard shown for topical oligopeptide‑1 (h=0,m=0). Exposure: increase by +1 for infants because skin barrier immaturity can increase dermal uptake compared with adults; although large peptides have low dermal penetration, measurable absorption cannot be ruled out for compromised/immature skin, so e=1 for 0–3 yr (sources: general dermal pharmacokinetic principles in PubMed, CosIng listing of peptide cosmetic use; no specific infant studies found).
- Comment VeriMom évalue-t-il oligopeptide-126 sh-oligopeptide-1 ?
- VeriMom évalue oligopeptide-126 sh-oligopeptide-1 à 100/100 (pas de risques connus) sur la base du statut EU CosIng, des classifications ECHA et des études PubMed.
- Quelles sont les alternatives sûres à oligopeptide-126 sh-oligopeptide-1 pendant la grossesse ?
- Consultez notre liste d'alternatives sûres à oligopeptide-126 sh-oligopeptide-1 basée sur une fonction similaire et une classification sans risques connus.
Vérifiez chaque étiquette en 2 secondes
Obtenez VeriMom gratuitement — scannez n'importe quel produit et voyez le score de sécurité grossesse instantanément.
Avis Médical
Ces informations sont fournies à titre éducatif uniquement et ne constituent pas un avis médical. Les scores de sécurité sont basés sur des données accessibles au public et peuvent ne pas refléter tous les risques. Consultez toujours votre professionnel de santé avant d'utiliser tout produit pendant la grossesse ou l'allaitement.